By searching for new drugs against fungal pathogens, we found that miltefosine is active against Aspergillus fumigatus clinical isolates. A library of transcription factors (TF) null mutants was then challenged with this drug and we discovered a novel TF that confers resistance to miltefonise, named here SmiA. By using ChIP-seq, we searched for SmiA targets upon miltefosine treatment. Overall design: The SmiA-tagged strain was grown for 16 hours at 37oC in minimum liquid media at 220 rpm and then transferred to RPMI added with 12.5 ug/ml of miltefosine for 30 minutes (37oC 220 rpm). After crosslinking, the cells were washed and frozen for chromatin extraction and immunoprecipitation.